Topics:
Head and Neck Cancers • Medical Oncology
Assuming a clinical trial is unavailable, would you consider tazemetostat in a patient with metastatic INI1/SMARCB1 deficient sinonasal carcinoma?
Has anyone tried this approach with success?
Answer from: Medical Oncologist at Academic Institution
I would certainly consider Tazmetostat for INI deficient SNUC, if progressed on front-line therapy and no trials available.
Sign in or Register to read more